Projects per year
Personal profile
Personal profile
Dr. Torre-Amione received his first academic appointment in 1995 as a Clinical Instructor at the Baylor College of Medicine in Houston, Texas. He became an Assistant Professor there one year later, the same year he became the Medical Director for the Cardiac Transplant Service at Houston Methodist DeBakey Heart and Vascular Center. Dr.Torre-Amione joined the Houston Methodist Specialty Physician Group and Weill Medical College in 2005.
Research interests
Dr. Torre-Amione is the director of the Heart Failure Research Laboratory at Houston Methodist, and conducts research examining the mechanisms of immune activation and inflammation as it relates to myocardial dysfunction in the areas of heart failure and cardiac transplantation. The doctor and his colleagues have conducted numerous studies that suggest novel immune modulatory therapies for the treatment of heart failure and transplant patients. Dr. Torre-Amione led the first two FDA-approved trials of Celacade with impressive results, and a Phase III trial is underway. Other studies underway in the Heart Failure Research Laboratory are investigating additional immune response pathways that contribute to the progression of heart failure, including the role of heat shock proteins and cardiac mast cells.
Education/Academic qualification
Interventional Cardiology, Clinical Fellowship, Baylor College of Medicine
Aug 1 1992 → Jun 30 1995
Award Date: Jun 30 1995
Internal Medicine, Residency, Baylor College of Medicine
Jul 1 1990 → Jul 30 1992
Award Date: Jul 30 1992
MD, Facultad De Medicina - Instituto Tech.
… → May 31 1985
Award Date: May 31 1985
Cardiology, Postdoctoral Fellowship, Baylor College of Medicine
Immunology, PhD, University of Chicago
Research Area Keywords
- Regenerative Medicine
Free-text keywords
- Heart failure
- Cardiac transplant
- Immune activation
- Inflammation
- Heat shock proteins
- Cardiac mast cells
Fingerprint
Dive into the research topics where Guillermo Torre-Amione is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 5 Finished
-
Effect of Everolimus Immunotherapy on Anti-HLA Antibody Mediated Activation of Endothelial Cells. A retrospective mechanistic substudy of â??A 24-month, multi-center, randomized, open-label study
Torre-Amione, G. & Bhimaraj, A.
University of California Los Angeles
11/30/12 → 12/31/13
Project: Non Profit
-
Effect of Plasma Exchange on patients with chronic refractory heart failure
Gulf Coast Regional Blood Center
10/15/07 → 10/30/08
Project: Non Profit
-
Genetic Modulation of Left Ventricular Recovery (University of Pittsburgh Reference Number 108216)
12/1/05 → 12/31/06
Project: Federal Funding Agencies
-
A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety
Rubio-Infante, N., Ramírez-Flores, Y. A., Castillo, E. C., Lozano, O., García-Rivas, G. & Torre-Amione, G., Mar 30 2022, In: Frontiers in Cell and Developmental Biology. 10, 851032.Research output: Contribution to journal › Article › peer-review
Open Access -
Early increase of serum ferritin among COVID-19 patients is associated with need of invasive mechanical ventilation and with in-hospital death
Ramonfaur, D., Aguirre-García, G. M., Diaz-Garza, C. A., Torre-Amione, G., Sanchez-Nava, V. M., Lara-Medrano, R., Ramírez-Elizondo, M. T., Esparza-Sandoval, A. C., Ortega-Hernández, F. J. & Martínez-Reséndez, M. F., 2022, (Accepted/In press) In: Infectious Diseases.Research output: Contribution to journal › Article › peer-review
-
Long term development of diastolic dysfunction and heart failure with preserved left ventricular ejection fraction in heart transplant recipients
Vejpongsa, P., Torre-Amione, G., Marcos-Abdala, H. G., Kumar, S., Youker, K., Bhimaraj, A. & Nagueh, S. F., Mar 9 2022, In: Scientific Reports. 12, 1, 3834.Research output: Contribution to journal › Article › peer-review
Open Access -
Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article ‘Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis’. Reply
Rubio-Infante, N., Ramírez-Flores, Y. A., Castillo, E. C., Lozano, O., García-Rivas, G. & Torre-Amione, G., 2022, (Accepted/In press) In: European Journal of Heart Failure.Research output: Contribution to journal › Letter › peer-review
-
Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score
Aguirre-García, G. M., Ramonfaur, D., Torre-Amione, G., Ramírez-Elizondo, M. T., Lara-Medrano, R., Moreno-Hoyos, J. F., Velázquez-Ávila, E. S., Diaz-Garza, C. A., Sanchez-Nava, V. M., Castilleja-Leal, F., Rhoades, G. M. & Martínez-Reséndez, M. F., 2022, (Accepted/In press) In: Pulmonology.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations